ERBB2 and breast carcinoma: HER-2 is present on the surface of EVs derived from HER2-positive breast cancer and binds to a therapeutic drug (trastuzumab) that targets HER-2 and consequently inhibits the therapeutic effect (Ciravolo et al., 2012).